Sample size and power issues in estimating incremental cost-effectiveness ratios from clinical trials data.
about
Cost-effectiveness of collaborative care for the treatment of depressive disorders in primary care: a systematic reviewUsing inverse-weighting in cost-effectiveness analysis with censored data.Health economic evaluation in lumbar spinal fusion: a systematic literature review anno 2005.Feasibility of using administrative claims data for cost-effectiveness analysis of a clinical trialBayesian methods for design and analysis of cost-effectiveness trials in the evaluation of health care technologies.How Chiropractors began working in a Community Health Centre in OttawaUnfinished symphony: a tribute to the life and career of Bernie O'Brien (1959-2004).Costs and effects in lumbar spinal fusion. A follow-up study in 136 consecutive patients with chronic low back pain.In search of pharmacoeconomic evaluations for fibromyalgia treatments: a review.Preventing postnatal maternal mental health problems using a psychoeducational intervention: the cost-effectiveness of What Were We Thinking.Sample size determination for cost-effectiveness trials.Power and sample assessments for tests of hypotheses on cost-effectiveness ratios.Cost-effectiveness inferences from bootstrap quadrant confidence levels: three degrees of dominance.Sample size and power for cost-effectiveness analysis (part 1).The Cost-Effectiveness of Measures to Prevent Recurrent Ankle Sprains: Results of a 3-Arm Randomized Controlled Trial.Incremental cost-effectiveness ratio and incremental net-health benefit: two sides of the same coin.
P2860
Q27024741-0C613047-34EA-4B4E-9610-33644BB3575EQ30760278-84818C30-5A3C-4CCB-8015-5D9E0C5CF123Q33230071-2CDCA3F1-5C38-4E8C-BD09-93427F25D99AQ33446356-11515347-FEBC-42DD-8F89-6695BFB3487CQ35040675-C90B877F-97A4-4C37-95B0-1954D3FB5366Q35729086-5EDE8B23-8073-4691-A3DB-7619A289A4BBQ35883442-00A18377-91B4-4E57-B1C2-76EAA878A4C6Q36404741-CA386C88-771B-47B3-9E2F-A40359C215B9Q36488214-F787A80D-E06F-4432-85B2-0C38A6069638Q37454031-0C0C81A4-7E22-4D2F-B7F1-0A308DAF9C3AQ37944317-9B49F25C-B9A2-48E4-8DFD-7123A2009131Q43537390-3C5A850A-3266-42F1-8366-9A8AE046878FQ46514162-BE2D70BC-5F0A-4928-9DE8-93CD014FE600Q47391808-5EFF36BF-345A-4A39-8D7B-45D2CB9E417BQ51144750-2EF98679-54A0-40FE-A4B9-C7D43DFEE6AAQ51642564-E08487D8-155B-48AC-AE0A-2871EF794792
P2860
Sample size and power issues in estimating incremental cost-effectiveness ratios from clinical trials data.
description
1999 nî lūn-bûn
@nan
1999 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
1999 թվականի մայիսին հրատարակված գիտական հոդված
@hy
1999年の論文
@ja
1999年論文
@yue
1999年論文
@zh-hant
1999年論文
@zh-hk
1999年論文
@zh-mo
1999年論文
@zh-tw
1999年论文
@wuu
name
Sample size and power issues i ...... ios from clinical trials data.
@ast
Sample size and power issues i ...... ios from clinical trials data.
@en
type
label
Sample size and power issues i ...... ios from clinical trials data.
@ast
Sample size and power issues i ...... ios from clinical trials data.
@en
prefLabel
Sample size and power issues i ...... ios from clinical trials data.
@ast
Sample size and power issues i ...... ios from clinical trials data.
@en
P2860
P1433
P1476
Sample size and power issues i ...... ios from clinical trials data.
@en
P2093
P2860
P304
P356
10.1002/(SICI)1099-1050(199905)8:3<203::AID-HEC413>3.0.CO;2-7
P407
P577
1999-05-01T00:00:00Z